



Published in final edited form as:

*Top Companion Anim Med.* 2010 November ; 25(4): 203–212. doi:10.1053/j.tcam.2010.09.002.

## Feline Genetics: Clinical Applications and Genetic Testing

**Leslie A. Lyons, PhD**

Department of Population Health & Reproduction, School of Veterinary Medicine, University of California - Davis, One Shields Avenue, Davis, California, 95616, USA, Phone: 01 530 754 5546, Fax: 01 530 752 4278

Leslie A. Lyons: lalyons@ucdavis.edu

### Abstract

DNA testing for domestic cat diseases and appearance traits is a rapidly growing asset for veterinary medicine. Approximately thirty-three genes contain fifty mutations that cause feline health problems or alterations in the cat's appearance. A variety of commercial laboratories can now perform cat genetic diagnostics, allowing both the veterinary clinician and the private owner to obtain DNA test results. DNA is easily obtained from a cat via a buccal swab using a standard cotton bud or cytological brush, allowing DNA samples to be easily sent to any laboratory in the world. The DNA test results identify carriers of the traits, predict the incidence of traits from breeding programs, and influence medical prognoses and treatments. An overall goal of identifying these genetic mutations is the correction of the defect via gene therapies and designer drug therapies. Thus, genetic testing is an effective preventative medicine and a potential ultimate cure. However, genetic diagnostic tests may still be novel for many veterinary practitioners and their application in the clinical setting needs to have the same scrutiny as any other diagnostic procedure. This article will review the genetic tests for the domestic cat, potential sources of error for genetic testing, and the pros and cons of DNA results in veterinary medicine. Highlighted are genetic tests specific to the individual cat, which are a part of the cat's internal genome.

### Keywords

domestic cat; DNA; feline; genetic testing; mutations

### Simple Genetic Traits

A cat's appearance, its phenotype, and its health can be influenced by both genetic (inherited) and non-genetic (environmental) influences. The diseases and traits that have known mutations, hence clearly heritable and genetic, are generally called simple genetic traits, as the presentations are controlled mostly by a single specific mutation in a single specific gene. Because these traits are "simple", most of the initially discovered mutations in any species have been for clearly genetic traits that have high frequencies in specific populations. The first mutations identified in cats were for lipid and lysosomal storage diseases in the early and mid-1990's<sup>1,2</sup>, [J1]as these diseases have well defined phenotypes and known genes with mutations that were as found in humans (See reviews<sup>3,4</sup>). Most of the common diseases, coat colors, and coat types have been deciphered in the cat following the same candidate gene approach, implying finding a replicate trait in another species and

---

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

checking the same gene for causative mutations. Presented in Table 1 are the commercially available simple genetic traits and diseases with known mutations in the cat. Other disease mutations are presented in Table 2. To date, other than the muscular dystrophy mutation<sup>1</sup>, all other mutations in the cat are autosomal, not found on the X or Y chromosomes.

The coat color mutations are common to all cats and are effective for genetic typing in all breeds and populations. However, even though long fur is common in breeds and random bred cats, long fur is an exception because four different mutations in *FGF5* can cause a cat to have long fur<sup>5,6</sup>[J2]. One mutation is common to most all breeds and populations, suggesting this mutation to be the most ancient mutation, but the others are more specific to particular breeds<sup>7</sup>. Thus, to determine accurately if a cat carries a mutation for long fur, all four mutations must be genotyped.

In contrast to coat colors and long fur, most of the identified disease tests in cats are very specific to breeds and populations. Most diseases are identified in cat breeds, which are a small percentage of the cat population of the world, perhaps at most 10–15% in the USA<sup>8</sup>. Some mutations that were found in a specific breed, such as mucopolysaccharidosis in the Siamese<sup>2,9</sup>, were found in a specific individual and the mutation is not actually prevalent in the breed (Table 2). These genetic mutations should not be part of routine screening by cat breeders and registries, but clinicians should know that genetic tests are available for diagnostic purposes, especially from research groups with specialized expertise, such as at the University of Pennsylvania (<http://research.vet.upenn.edu/penngen>). Other biomarkers are also available at these specialized laboratories to help decipher between the lysosomal storage and metabolism orders. Other diseases, such as polycystic kidney disease (PKD), are prevalent, PKD in Persians is estimated at 30–38% worldwide<sup>10–12</sup>. Because of cross breeding with Persians, many other breeds, such as British Shorthairs, American Shorthairs, and Scottish Folds, also need to be screened for PKD<sup>13–15</sup>. Thus, veterinarians need to be aware of cross-breeding practices, which differ in different cat registry organizations, so that genetic tests can be placed as high or low priority for differentials and diagnostics.

Non-genetic components, including toxins, infections, infestations, sporadic damage and changes to the DNA, and environmental influences, such as diet, exercise and social surroundings, can produce a phenotype that looks just like an inherited characteristic or disease, a phenocopy. Detailed examinations of cats with heart murmurs may reveal different presentations of heart disease, one that may be genetic and one that may be environmentally induced, such as by low dietary taurine resulting in dilated cardiomyopathy<sup>16</sup>. Some diseases may present differently in different tissues, termed as pleiotropic effects of the same gene. For example, completely white cats can be just white, while others have blue eyes or odd-eyed color and some may be deaf<sup>17–19</sup>. Genetic testing can assist the clinician to rule out the common and environmental causes of clinical presentations versus a condition caused by a heritable defect in the cat's DNA.

## Hallmarks of Genetic Diseases

A cat's phenotype is a combination of the presence of diseases, visible traits, or morphological types. Attributes of the phenotype can be desirable or undesirable, especially in the case of diseases. Because phenotypes can be a result of a single gene, the interaction of several genes, the accumulation of environmental exposures, or of a combination of interactions, a veterinarian may choose different types of therapy, clinical management, or make different prognoses if a phenotype is known to be genetic. If the same condition is found in other species, a veterinarian may have opportunities to try novel approaches for health care by considering comparative medicine. Several characteristics are common to

genetic diseases that will help decipher sporadic, idiopathic, occurrences from inherited conditions.

The six common hallmarks for inherited diseases include; 1) early age of onset, 2) bilateral and/or multiple presentation, 3) presence in a closed or small population, 4) indications of inbreeding, 5) uniformity in presentation, and 6) advanced parental age at birth. Only advanced age of parents at birth has not been shown to have an effect in cat inherited diseases. In humans, older mothers have a higher frequency of having children with Trisomy 21<sup>20</sup> and dwarfism is associated with advanced paternal age<sup>21</sup>.

Two examples of diseases that present as sporadic and inherited forms are PKD<sup>22</sup> and lymphosarcoma<sup>8</sup>. Each of the five characteristics that define genetic diseases can help identify PKD from cats with sporadic kidney cysts. Kidney cysts can occur in any cat but not all cystic presentations are indicative of PKD. PKD can sometimes be detected as early as 6 to 8 weeks of age by ultrasound, consistently by 10 months of age<sup>14</sup>. Both kidneys are normally affected and multiple cysts are generally present. The cysts are not similar in size but are similar in etiology. PKD is rampant in Persian cats, thus must be considered to be present in related breeds, such as Exotic shorthairs and Himalayans. Surprisingly, this genetic problem has a very high frequency in one of the oldest and largest cat breeds, thus not a small or closed population, but the early onset, bilateral presentation, and the high prevalence in a breed clearly demarcate this condition as a heritable problem. An older, random bred cat with one kidney cyst in one kidney would not be a candidate for PKD and genetic testing.

Lymphosarcoma is also frequent in cats but it is generally found in older cats and/or cats that have been infected and are positive for FeLV<sup>23</sup>. An usual rate of mediastinal lymphosarcoma has been specifically identified in silver Oriental Shorthairs that are FeLV negative and generally younger than 2 years of age. Not only is a breed influence suspected in this disease, but even a particular color or line. Other related breeds, such as Siamese, Colorpoint shorthairs and the longhaired varieties of Siamese should be suspected of having a prevalence of this lymphoma. Age of onset is 1–2 years and the tumors respond well to chemotherapy, but reoccur with a poor prognosis. Thus, this disease is found in a closed, inbred population, has an early onset and generally uniform presentation and the tumor is found in areas not common to older onset forms of lymphosarcoma. These hallmarks define a heritable condition versus sporadic lymphomas occurring in older aged cats.

## Genetic Risk Factors and Complex Traits

A genetic problem with a high frequency can be found in nearly every breed, thus no one breed can generally be considered healthier than another. Detrimental genes are found in random bred cats as well, but low inbreeding prevents an increased incidence in presentation of the disease. However, for recessive or dominant diseases that do not cause early clinical presentations, breeders can be completely unaware of the propagation of a deleterious gene. Some breeds may also have health problems, genetic and non-genetic, due to the conformation or “type” desired for the breed. Shortened skull structures and nasal canals cause Persians to have weeping eyes, asymmetric skulls and poor bite<sup>24</sup>. Anecdotally, the fine, elegant structures of Abyssinians and Siamese exacerbate patellar luxation. The largest breed, the Maine Coon, is under investigation for hip dysplasia[J3], a very common problem in large dog breeds. Likely, these more complex problems have a genetic component, but determining the number and the affect of genes is difficult, thus, recommendations for better breeding practices could be of more value than genetic testing.

All the mutations influencing a disease may not be identified at any given time, thus, usually the mutations that influence a condition the most, have the highest heritability, are identified

first. Because multiple mutations may act additively to cause a disease, each mutation may be said to confer a “risk” for disease development. Thus, some mutations may be considered risk factors, predisposing an individual to health problem. These risk conferring mutations are neither necessary nor sufficient for causing disease. An excellent example of mutations that confer a risk are the DNA variants associated with cardiac disease in cats.

Hypertrophic cardiomyopathy (HCM) is a recognized genetic condition in cats<sup>25</sup>. In 2005, Drs. Meurs, Kittleson and colleagues published that a DNA alteration in the gene cardiac *myosin-binding protein C 3 (MYBPC3)* was strongly associated with HCM in a long-term research colony of Maine Coon cats at UC Davis<sup>26</sup>. The DNA mutation is commonly referred to as A31P, as this DNA mutation changes codon 31 from an alanine to a proline in the amino acid sequence (i.e., protein) of cMYBPC. The data clearly shows that not all cats with the mutation had HCM and that some cats with HCM did not have the DNA mutation. Age of onset, variable expression, and disease heterogeneity were alluded to in this report. These aspects suggest that the identified DNA variant should to be considered more of a “risk factor” than a directly causative mutation. Two recent papers have shown that not all Maine Coon cats with the A31P mutation get HCM<sup>27,28</sup> and one of those papers has mistakenly interpreted this lack of penetrance as being evidence that the A31P mutation is not causal<sup>28</sup>. This interpretation is misleading, causing debate as to the validity of the Maine Coon HCM test.

To date, most cat genetic tests have been for traits that have nearly complete penetrance, have little variability in expression, and are early in onset. However, some imperfect examples do exist in cats that have not caused as much controversy as the HCM test. The *CEP290* PRA mutation in Abyssinians has a late age of onset and some cats with subclinical disease have been identified<sup>29</sup>. Some cats with the pyruvate kinase deficiency can have very mild and subclinical presentations<sup>30</sup>. The interplay of various coat color genes often muddle the determination of the true coat color of cats. As true in humans with cardiac disease, the finding that not all cats with the A31P mutation in *MYBPC3* get HCM is actually usual in the field of HCM genetic testing. Thus, disease or trait causing mutations may not be 100% penetrant, thus, they do not always cause clinically detectable disease. Presence of clinical disease in an individual cat and the severity of disease (expression) is likely affected by the known genetic aspects presented below:

- 1. Incomplete Penetrance** – for some traits and diseases, even though a known causative mutation has been identified, an individual with that mutation does not present with the condition. Incomplete penetrance is an extreme of variable expression (see below). In general, the reason as to why a condition would not present is unknown, but other genetic, biological, and environmental interactions certainly play a role in the overall appearance and health of an individual and its organs. The sensitivity of clinical diagnostics may also influence the determination of penetrance. In the case of HCM, echocardiography (cardiac ultrasound) can be considered an insensitive tool for detecting mild forms of HCM in cats, thus, many cats with mild do not clinically appear to have cardiac disease. Experience and bias also play a role in diagnosis. For example, individuals who do not have expertise with ultrasonic examinations for HCM or PKD are less likely to be able to provide an accurate diagnosis for these diseases.
- 2. Age of Onset** (age-related penetrance) – some diseases have a slow progression and may not present until later in life. In humans, HCM due to *MYBPC* mutations is clearly a disease that has slow progression and commonly does not express until the individual is over 50 years of age. HCM in Maine Coon cats can also develop in older cats, especially in cats that are heterozygous for the mutation (carry only one copy of the mutated gene) and, for some unknown reason, in females. Often, an

autosomal dominant disease may be more severe if two copies of the risk mutation are present in an individual, leading to earlier and more severe disease, which appears to be the case with the A31P mutation. The definitive age as to when a cat is clear of developing HCM is not precisely determined.

3. **Variable Expression** – most traits and diseases have some amount of variable expression depending on the individual. For example, not all cats with the mutation for blue dilution have the same color of blue/gray. Obviously, the background genetics and environment of the individual influence the overall presentations of traits and diseases. Thus, the level of presentation can be variable in regard to left ventricular wall thickness in cats with HCM. Cats can have mild, moderate or severe HCM. Only those cats with severe HCM show clinical signs although a few cats with lesser severity of disease may die suddenly. Cats with HCM may fall in the “equivocal” range for wall thickness, thus, definitive affected status is difficult to declare. These equivocal cats may progress to more severe disease with time, or the equivocal status may be as severe as the disease gets. Some cats with PKD have only a few cysts and never progress to renal failure, others have severe and fast progression of disease and succumb renal failure in a few years.
4. **Disease Heterogeneity** – often, more than one mutation in the same gene, or mutations in different related genes can cause the same disease. Genetic heterogeneity for HCM in humans is well established, thus, there is no reason to not think the same situation is true for cats. Currently over 1000 mutations in over 10 genes are known to cause HCM in humans. Only two mutations have been identified that cause HCM in cats, the A31P mutation in Maine Coon cats and the R820W mutation in Ragdolls<sup>26,31</sup>, which also causes disease in humans<sup>32</sup>. Both mutations are in *MYBPC3*, the most commonly mutated gene in humans with HCM (see review<sup>33</sup>). Other breeds of cats including Bengals, Siberians, Devon Rex, and Sphynx and mixed breed cats either do not have or have an extremely low prevalence of the A31P or the R820W mutation. However, there are Maine Coon cats that have HCM that do not have the A31P mutation and so there has to be at least one more cause of HCM, most likely another mutation, in this breed. The long fur mutations in the cat are examples of trait heterogeneity.
5. **Genetic Testing Accuracy** – even though a specific genetic mutation may be identified for a genetic trait or disease, research laboratories use different methods to assay for the mutation. Errors in genetic assays may produce inaccurate DNA results, leading to the confusion of genetic test interpretation. Direct DNA sequencing is considered the most robust method, “the Gold Standard,” but also one of the more costly methods of analysis. Because DNA primers must bind to the DNA sequence flanking a specific mutation, other, unimportant mutations may be in the areas where the primers bind, causing poor or no amplification of one or both alleles for a given individual. This condition is known as allelic drop-out and all testing laboratories are aware of this potential source of error for a genetic test. Even direct DNA sequencing can suffer from allelic drop-out, but because a larger portion of the gene which may have other DNA variants is generally amplified, a higher likelihood of detecting allelic drop-out is available. Laboratories will place PCR primers in different locations surrounding the mutation of interest, which is often proprietary information, in attempts to lower the risk of allelic drop-out. Thus, some laboratories have better assays than others, even if they are doing the same assay method and testing for the same mutation. The different DNA assay methods are usually developed to reduce cost and to fit the laboratory’s expertise and instrumentation. But, some assays may have, in general, some increased risk of test failure. Different common methods for DNA testing include real-time PCR

(TaqMan), restriction fragment length polymorphism (RFLP), allele-specific oligos (ASO), or even now mass spectroscopy-based methods. Just as a veterinarian may want to know if a FIV test is performed by a SNAP test, versus an ELISA, versus a Western Blot because each method has different sensitivities and specificities, so too is true for DNA testing methods. Veterinarians will need to become familiar with the different genetic testing approaches and not hesitate to ask a testing laboratory about their methods and sensitivity and specificity for their approaches.

- 6. Inaccurate Clinical Diagnosis** – Ultrasonic examination of the heart, echocardiography, is the most common and currently the only useful method for detecting cardiac disease in cats. Several studies have evaluated HCM presence in domestic shorthair and Maine Coon cats<sup>34–36</sup>. Not all cardiac disease is HCM and even the definition of HCM can be debated. A consistent definition for HCM is not always used by all cardiologists, thus, there is some difficulty with correlating a genetic test result with an ultrasound report, especially if detailed diagnostic criteria are not presented in the report. Misinterpretations in ultrasound examinations may lead to different interpretations with disease status.

Overall, the only way to determine the true risk conferred by some mutations is to follow cats over the course of their lifetime with common diagnostic procedures and comparing to the genetic test results. Only time and continued follow-up will help determine the true relative risk that mutations convey for complex diseases. In the case of HCM, various studies have indicated higher or lower risks in different populations of cats, but none have been able to follow cats throughout their lifetime. These studies are important and are of great value to the community. Other mutations need to be found and the cooperation of breeders must be positive and enthusiastic to have successful studies.

### Breeding Recommendations

Cat breeders are very knowledgeable in regards to weighing different factors to produce healthy cats that are of good type and temperament. Many genetic tests help a breeder make a clearer, more educated decision. Cats with a positive genetic test for diseases should be screened by other diagnostics, such as ultrasound in the case of HCM and PKD, to determine disease status and this overall information used in breeding decisions. Other health, type, and behavioral attributes should certainly be considered in the overall breeding program. However, breeders need to work hard to reduce the risks with any health issue. With the HCM A31P mutation, every cat that has the mutation is at risk for developing HCM and every cat with the mutation will pass it on to some or all of its offspring. Cats that are homozygous for the A31P mutation will definitely pass the mutation to their offspring. The homozygous cats are at high risk of developing severe HCM. Cats that are heterozygous for the mutation should not be bred unless they have other qualities that are either highly beneficial or necessary to the breed. Kittens that test negative for the mutation should be used to replace them in the gene pool. A slow eradication of disease is recommended for highly prevalent diseases, such as HCM and PKD, as quick elimination of such a high number of cats could lead to other effects of inbreeding depression. Breeds with very low population sizes, such as Korats, have learned to manage the gangliosidoses in their breed, never breeding carriers together. Hopefully, all the disease mutations can be eventually eradicated, but good breeding decisions and balancing population diversity must be considered.

### Genetic Testing Concerns in Different Breeds or Populations

Once a mutation is identified for a gene, which causes a particular coat color or disease, a service laboratory, either in association with the investigator who found the mutation, or an independent commercial laboratory, will establish a genetic test for that mutation to offer to

the public (Table 3). Nearly a dozen laboratories around the world now offer the genetic test for PKD in cats. All the laboratories may be technically very good and accurate, but, not all of them equally “know their cats”. Thus, some of the concerns with specificity and sensitivity of genetic tests, particularly in regard to testing in hybrid cat breeds, is due to a lack of knowledge of how cat breeds are developed and cat evolutionary relationships.

In Tables 1 are all the known genetic mutations in the cat that have been published and may be of concern for genetic testing. In the case of diseases, usually diseases present in a specific breed, thus only associated with that breed. However, some breeds are allowed to outcross with others and some are legal or illegally used to help refine the “look” of another breed. Siamese and Persians both have a host of other cat breeds that they have influenced. Hence, any mutation found in one breed can be found in others if cross breeding has occurred. In addition, cats are bred all over the world and the rules between registries and associations are not always the same. An outcross that may be acceptable for The International Cat Association (TICA) in the USA may be unacceptable for the Cat Fanciers’ Association (CFA) or perhaps the Governing Council of the Cat Fancy (GCCF) in the United Kingdom. Thus, testing laboratories need to understand some of these cat breed dynamics so that they know a test is valid for a given breed in any part of the world and so that tests are freely offered for the breeds at risk.

Why does one care if a genetic test is valid in a different breed? The concern is disease heterogeneity. As owners, breeders and veterinarians, we see a clinical presentation that is abnormal in the cat. However, any of us can quickly jump to conclusions. Cats have many causes of renal failure, not all renal failure is caused by PKD. Cats have different types of cardiac disease, not all cardiac disease is HCM. Even when a diagnosis of HCM is definitive, not all HCM is caused by the same mutation. Herein lies the concern. An unknowing veterinarian, owner, or breeder may want a cat to have a genetic test for HCM or PKD because the cat has clinical signs consistent with these diseases. If the test shows a negative result, this result does not mean the cat does not have HCM or PKD, if the test has not been proven in that selected breed. But, the result does imply that the cat does not have the mutation causing Maine Coon or Ragdoll HCM or Persian cat PKD. A laboratory may very well run the test, but laboratories have different capabilities and skills with genetic counseling. The veterinarian may be on their own to understand the meaning of a negative test, hence why a test is generally listed for pertaining to a specific breed. Until enough cats from a particular breed come forward with clinical data, such as ultrasound diagnoses and genetic test results, a test cannot be valid for the breed unless clear outcrossing to the risk breeds is apparent.

Besides knowing cats[J4], testing laboratories need to know their genetics as well. The protein sequence for the genetic mutation in the gene *Tyrosinase*, which causes the “points” mutation common to Siamese cats<sup>37</sup>, is presented in Figure 1a. Some positions in the sequence have different amino acids between the species, more between cats and humans than between cats and dog since cats and dogs have a closer evolutionary history. These protein alterations are normal differences between humans, dogs, and cats. But, the change of a glycine (G) to an arginine (R) within the cat is what makes a cat have “points”. This simple mutation causes temperature sensitivity in the protein, the protein that produces the melanin, which then only functions in areas where the cat’s body temperature is lower, the face, paws, ears and tail, the “points.” However, in the DNA sequence (Figure 1b), three nucleotides join together to code for one amino acid. Hence, the DNA sequence is three times longer than the protein sequence for a given protein. Four nucleotides (A is adenine, G is guanine, C is cytosine and T is thymidine) make up DNA. The coding of amino acids has built in redundancy. The amino acid glycine can be coded by the DNA sequence GGG, GGC, GGA, or GGT. The single nucleotide change of the guanine (G) to the adenine (A)

changes the amino acid from glycine to arginine and this makes the cats have points when both copies of their DNA has the same change. A mutation can occur at any nucleotide site. If the CCT became CCC, the thymidine (T) changes to a cytosine (C). This change does not alter the amino acid, it still codes for proline. This type of mutations is called a silent mutation, as it does not affect the protein. When hunting for important mutations, the silent mutations are generally discounted, being normal genetic variation found between individuals or species. A mutation that does not change the amount, expressing timing or structure of the protein generally will not have a change have an effect on phenotype or health. However, these silent mutations and DNA variants can wreak havoc with a genetic test. For example, a Siberian cat from Italy with yellow eyes that was dominant white was presented for genetic testing to determine the underlying coat color alleles. The genetic test for the *Color (TYR)* mutations suggested the cat was homozygous for the pointed mutation. If so, the cat had to have blue eyes, regardless of being dominant white. In this case, the cat had the normal, but silent, variant in the sequence around the mutation for points (Figure 1c). Notice the cat has only one allele for points, the bottom line, but the top line has the silent mutation. Because the sequence was not the normal sequence before the important mutation site, the test failed for that allele and the test result suggest the cat was homozygous for points. A good laboratory knows this can happen and has other ways to detect these anticipated problems. Because the laboratory had strong interactions with the breeders, the test was redesigned to account for this anomaly.

### Genetic Testing Concerns in Hybrid Cat Breeds

The normal level of variation between cats is expected, being far less than 1% of a sequence that codes for a protein. Herein lies a problem for hybrid cat breeds. The evolutionary time between cat species is millions of years<sup>38</sup>, not hundreds to thousands between cat breeds and populations. An Asian leopard cat had a common ancestor with the domestic cat about 6 million years ago, the bobcat about 8 million years ago, the Serval about 9.5 million years ago. The Jungle cat is more closely related to a domestic cat than the leopard cat to the domestic cat.[J5] In addition, for some of these wild felid species, different subspecies have been incorporated into the breed. The DNA sequence between a domestic cat and one of these wild felid species will have many genetic differences, maybe a several percentage difference, less for the Jungle cat, more for Serval as compared to a domestic cat. The genetic differences are most likely silent mutations, but, the variation will interplay with genetic assays and may cause more allelic drop-out than what would be normally anticipated. No genetic tests have been validated in the hybrid cats breeds, although they are typically used very frequently.

Most labs recognize that disease mutations are specific to breeds, but, not the coat colors. The coat color mutations occurred during the early domestication of the cat before the breeds were developed, so, all breeds tend to have the same mutation. This is true for all the coat color tests so far but for the hybrid breeds, such as Bengals, Chaussies, and Savannahs, some oddities in coat color and disease testing may occur. The normal DNA sequence around each one the mutations for coat colors needs to be evaluated in many individuals from each wild felid species in order to find the normal, silent mutations that occur between the wild felids and the domestic cats. At any given gene, in a Bengal, one never knows if you have one leopard cat sequence or two are present. Thus, the accuracy for any genetic test is in no known for hybrid cat breeds. If the domestic cat alleles are present, the test will perform as expected. But, one never know when one allele or both are from the leopard cat. Which, generally, selection is favoring the wild felid colorations, so, inherently, the breed is selected for the DNA sequences that may cause the genetic tests to fail.



## Other Inappropriate Genetic Testing

Genetic testing laboratories attempt to provide the best services for the lowest costs. Many of the newer technologies allow for higher throughput of samples, as well as performing more than one genetic test in one assay, greatly lowering costs of reagents and manpower. Many testing laboratories are seeking to be as complete as possible, providing all available genetic tests for any given species. However, in the zeal of competition, a few genetic tests that are offered in the cat do not have sufficient scientific support. Any genetic test should have a publication that can be referenced to determine the genetic sequence surrounding the mutation, and provide the statistical support for the accuracy of the mutation for conferring disease or the trait of interest in specific breeds and populations. Published abstracts are not peer-reviewed articles and do not have sufficient information to determine the accuracy of a test, thus, abstracts are not appropriate references for genetic tests. Some universities or researchers have spin-off companies and their discoveries may be protected by licensure or patent, possibly never publishing the data for competitive advantage. Thus, some genetic tests can only be found with specific testing companies. Currently, the patented tests for cats include PKD, HCM, the mutations for *Tyrosinase* at the Color locus that confer Siamese and Burmese style “points” and Type B blood type<sup>39</sup>. However, licensure is available for each of these tests and the patents only pertain to the USA. Some companies will violate these patents as the overall income to the university is generally very low, thus, the likelihood that a university would enforce a patent would be low as the cost would be prohibitive. However, violation of genetic test patents is not encouraged and generally considered inappropriate.

Besides patent violations, some laboratories will offer genetic tests that are not scientifically sound to appear to gain a competitive advantage. A mutation in *MYBPC3* for HCM was reported in an abstract, but was never presented in a peer-reviewed publication. No support for the risk this mutation confers for HCM in cats has been well documented, but some laboratories offer the test for this DNA variant. Laboratories will post disclaimers, often leaving the veterinarian, owner and breeder to speculate as to the tests overall influence to the cats help.

## Conclusion

Genetic testing is an important diagnostic tool for the veterinarian, breeder, and owner. Genetic tests are not 100% foolproof and the accuracy of the test procedure and the reputation and customer service of the genetic testing laboratory needs to be considered. Some traits are highly desired and genetic testing can help breeders to more accurately determine appropriate breedings, potentially becoming more efficient breeders, thus lowering costs and excess cat production. Other traits or diseases are undesired, thus genetic testing can be used to prevent disease and potentially eradicating the concern from the population. Genetic tests for simple genetic traits are more consistent with predicting the trait or disease presentation, but, as genomics progress for the cat, more tests that confer risk will become more common. Veterinarians will have to weigh the relative risk of having a mutation versus having disease as part of their differentials and breeders will have to consider risk factors along with the other important attributes of a cat for their breeding decisions.

## Acknowledgments

Funding support is provided by NIH-NCRR RR016094, the Winn Feline Foundation, and the Center for Companion Animal Health, School of Veterinary Medicine, University of California, Davis.

## References

1. Winand NJ, Edwards M, Pradhan D, et al. Deletion of the dystrophin muscle promoter in feline muscular dystrophy. *Neuromuscul Disord.* 1994; 4:433–445. [PubMed: 7881288]
2. Yogalingam G, Litjens T, Bielicki J, et al. Feline mucopolysaccharidosis type VI. Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease. *J Biol Chem.* 1996; 271:27259–27265. [PubMed: 8910299]
3. Banks G, Chamberlain J. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. *Curr Top Dev Biol.* 2008; 84:431–453. [PubMed: 19186250]
4. Valayannopoulos V, Nicely H, Harmatz P, et al. Mucopolysaccharidosis VI. *Orphanet J Rare Dis.* 2010; 5:1–20. [PubMed: 20074341]
5. Drogemuller C, Rufenacht S, Wichert B, et al. Mutations within the FGF5 gene are associated with hair length in cats. *Anim Genet.* 2007; 38:218–221. [PubMed: 17433015]
6. Kehler JS, David VA, Schaffer AA, et al. Four independent mutations in the feline fibroblast growth factor 5 gene determine the long-haired phenotype in domestic cats. *J Hered.* 2007; 98:555–566. [PubMed: 17767004]
7. Bach, L.; Gandolfi, B.; Grahn, R., et al. The distribution and possible origins of FGF5 mutations affecting fur length in cats. 2010. submitted
8. Louwerens M, London CA, Pedersen NC, et al. Feline lymphoma in the post-feline leukemia virus era. *J Vet Intern Med.* 2005; 19:329–335. [PubMed: 15954547]
9. Yogalingam G, Hopwood JJ, Crawley A, et al. Mild feline mucopolysaccharidosis type VI. Identification of an N-acetylgalactosamine-4-sulfatase mutation causing instability and increased specific activity. *J Biol Chem.* 1998; 273:13421–13429. [PubMed: 9593674]
10. Cannon MJ, MacKay AD, Barr FJ, et al. Prevalence of polycystic kidney disease in Persian cats in the United Kingdom. *Vet Rec.* 2001; 149:409–411. [PubMed: 11678212]
11. Barrs VR, Gunew M, Foster SF, et al. Prevalence of autosomal dominant polycystic kidney disease in Persian cats and related-breeds in Sydney and Brisbane. *Aust Vet J.* 2001; 79:257–259. [PubMed: 11349412]
12. Barthez PY, Rivier P, Begon D. Prevalence of polycystic kidney disease in Persian and Persian related cats in France. *J Feline Med Surg.* 2003; 5:345–347. [PubMed: 14623204]
13. Biller DS, Chew DJ, DiBartola SP. Polycystic kidney disease in a family of Persian cats. *J Am Vet Med Assoc.* 1990; 196:1288–1290. [PubMed: 2185204]
14. Eaton KA, Biller DS, DiBartola SP, et al. Autosomal dominant polycystic kidney disease in Persian and Persian-cross cats. *Vet Pathol.* 1997; 34:117–126. [PubMed: 9066078]
15. Lyons LA, Biller DS, Erdman CA, et al. Feline polycystic kidney disease mutation identified in PKD1. *J Am Soc Nephrol.* 2004; 15:2548–2555. [PubMed: 15466259]
16. Pion P, Kittleson M, Rogers Q, et al. Taurine deficiency myocardial failure in the domestic cat. *Prog Clin Biol Res.* 1990; 351:423–430. [PubMed: 2236148]
17. Bamber RC. Correlation between white coat colour, blue eyes, and deafness in cats. *J Genetics.* 1933; 27:407–413.
18. Wilson TG, Kane F. Congenital deafness in white cats. *Acta Otolaryngologica.* 1959; 50:269–275. discussion 275–267.
19. Bergsma DR, Brown KS. White fur, blue eyes, and deafness in the domestic cat. *J Hered.* 1971; 62:171–185. [PubMed: 5137350]
20. Nakata N, Wang Y, Bhatt S. Trends in prenatal screening and diagnostic testing among women referred for advanced maternal age. *Prenatal Diagnosis.* 2010; 3:198–206. [PubMed: 20063323]
21. Orioli I, Castilla E, Scarano G, et al. Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta. *Am J Med Genet.* 1995; 59:209–217. [PubMed: 8588588]
22. Biller DS, DiBartola SP, Eaton KA, et al. Inheritance of polycystic kidney disease in Persian cats. *J Hered.* 1996; 87:1–5. [PubMed: 8742815]
23. Gabor LJ, Malik R, Canfield PJ. Clinical and anatomical features of lymphosarcoma in 118 cats. *Aust Vet J.* 1998; 76:725–732. [PubMed: 9862061]

24. Schlueter C, Budras K, Ludewig E, et al. Brachycephalic feline noses: CT and anatomical study of the relationship between head conformation and the nasolacrimal drainage system. *J Feline Med Surg.* 2009; 11:891–900. [PubMed: 19857852]
25. Kittleson MD, Meurs KM, Munro MJ, et al. Familial hypertrophic cardiomyopathy in maine coon cats: an animal model of human disease. *Circulation.* 1999; 99:3172–3180. [PubMed: 10377082]
26. Meurs KM, Sanchez X, David RM, et al. A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy. *Hum Mol Genet.* 2005; 14:3587–3593. [PubMed: 16236761]
27. Sampedrano C, Chetboul V, Mary J, et al. Prospective Echocardiographic and Tissue Doppler Imaging Screening of a Population of Maine Coon Cats Tested for the A31P Mutation in the Myosin-Binding Protein C Gene: A Specific Analysis of the Heterozygous Status. *J Vet Intern Med.* 2009; 23:91–99. [PubMed: 19175727]
28. Wess G, Schinner C, Weber K, et al. Association of A31P and A74T polymorphisms in the myosin binding protein C3 gene and hypertrophic cardiomyopathy in Maine Coon and other breed cats. *J Vet Intern Med.* 2010; 24:527–532. [PubMed: 20412438]
29. Menotti-Raymond M, David VA, Pflueger S, et al. Widespread retinal degenerative disease mutation (rdAc) discovered among a large number of popular cat breeds. *Vet J.* 2009
30. Kohn B, Fumi C. Clinical course of pyruvate kinase deficiency in Abyssinian and Somali cats. *J Feline Med Surg.* 2008:10.
31. Meurs KM, Norgard MM, Ederer MM, et al. A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy. *Genomics.* 2007; 90:261–264. [PubMed: 17521870]
32. Ripoll Vera T, Monserrat Iglesias L, Hermida Prieto M, et al. The R820W mutation in the MYBPC3 gene, associated with hypertrophic cardiomyopathy in cats, causes hypertrophic cardiomyopathy and left ventricular non-compaction in humans. *Int J Cardiol.* 2010 Jun 12. [Epub ahead of print].
33. Tsoutsman T, Bagnall R, Semsarian C. Impact of multiple gene mutations in determining the severity of cardiomyopathy and heart failure. *Clin Exp Pharmacol Physiol.* 2008; 35:1349–1357. [PubMed: 18761664]
34. Fries R, Heaney AM, Meurs KM. Prevalence of the myosin-binding protein C mutation in Maine Coon cats. *J Vet Intern Med.* 2008; 22:893–896. [PubMed: 18498321]
35. Gundler S, Tidholm A, Haggstrom J. Prevalence of myocardial hypertrophy in a population of asymptomatic Swedish Maine coon cats. *Acta Vet Scand.* 2008; 50:22. [PubMed: 18564408]
36. Paige CF, Abbott JA, Elvinger F, et al. Prevalence of cardiomyopathy in apparently healthy cats. *J Am Vet Med Assoc.* 2009; 234:1398–1403. [PubMed: 19480619]
37. Lyons LA, Imes DL, Rah HC, et al. Tyrosinase mutations associated with Siamese and Burmese patterns in the domestic cat (*Felis catus*). *Animal Genetics.* 2005; 36:119–126. [PubMed: 15771720]
38. Johnson WE, Eizirik E, Pecon-Slattey J, et al. The late Miocene radiation of modern Felidae: a genetic assessment. *Science.* 2006; 311:73–77. [PubMed: 16400146]
39. Bighignoli B, Niini T, Grahn RA, et al. Cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH) mutations associated with the domestic cat AB blood group. *BMC Genet.* 2007; 8:27. [PubMed: 17553163]
40. Eizirik E, Yuhki N, Johnson WE, et al. Molecular genetics and evolution of melanism in the cat family. *Curr Biol.* 2003; 13:448–453. [PubMed: 12620197]
41. Peterschmitt M, Grain F, Arnaud B, et al. Mutation in the melanocortin 1 receptor is associated with amber colour in the Norwegian Forest Cat. *Anim Genet.* 2009; 40:547–552. [PubMed: 19422360]
42. Lyons LA, Foe IT, Rah HC, et al. Chocolate coated cats: TYRP1 mutations for brown color in domestic cats. *Mamm Genome.* 2005; 16:356–366. [PubMed: 16104383]
43. Schmidt-Kuntzel A, Eizirik E, O'Brien SJ, et al. Tyrosinase and tyrosinase related protein 1 alleles specify domestic cat coat color phenotypes of the albino and brown loci. *J Hered.* 2005; 96:289–301. [PubMed: 15858157]

44. Imes DL, Geary LA, Grahn RA, et al. Albinism in the domestic cat (*Felis catus*) is associated with a tyrosinase (TYR) mutation. *Anim Genet.* 2006; 37:175–178. [PubMed: 16573534]
45. Ishida Y, David VA, Eizirik E, et al. A homozygous single-base deletion in *MLPH* causes the dilute coat color phenotype in the domestic cat. *Genomics.* 2006
46. Gandolfi, B.; Bach, L.; Beresford, L., et al. Off with the gloves: Mutation in *KIT* implicated for the unique white spotting phenotype of Birman cats. 2010. submitted
47. Gandolfi B, Outerbridge C, Beresford L, et al. The Naked Truth: Sphynx and Devon Rex cat breed mutations in *KRT71*. *Mammalian Genome.* 2010 in press.
48. De Maria R, Divari S, Bo S, et al. Beta-galactosidase deficiency in a Korat cat: a new form of feline GM1-gangliosidosis. *Acta Neuropathol (Berl).* 1998; 96:307–314. [PubMed: 9754965]
49. Bradbury AM, Morrison NE, Hwang M, et al. Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase beta-subunit deficiency. *Mol Genet Metab.* 2009; 97:53–59. [PubMed: 19231264]
50. Muldoon LL, Neuwelt EA, Pagel MA, et al. Characterization of the molecular defect in a feline model for type II GM2-gangliosidosis (Sandhoff disease). *Am J Pathol.* 1994; 144:1109–1118. [PubMed: 8178934]
51. Martin DR, Cox NR, Morrison NE, et al. Mutation of the GM2 activator protein in a feline model of GM2 gangliosidosis. *Acta Neuropathol.* 2005; 110:443–450. [PubMed: 16200419]
52. Menotti-Raymond M, David VA, Schaffer AA, et al. Mutation in *CEP290* discovered for cat model of human retinal degeneration. *J Hered.* 2007; 98:211–220. [PubMed: 17507457]
53. Menotti-Raymond M, Deckman K, David V, et al. Mutation discovered in a feline model of human congenital retinal blinding disease. *Invest Ophthalmol Vis Sci.* 2010; 51:2852–2859. [PubMed: 20053974]
54. Fyfe JC, Menotti-Raymond M, David VA, et al. An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential *LIX1* function for motor neuron survival. *Genome Res.* 2006; 16:1084–1090. [PubMed: 16899656]
55. Martin DR, Krum BK, Varadarajan GS, et al. An inversion of 25 base pairs causes feline GM2 gangliosidosis variant. *Exp Neurol.* 2004; 187:30–37. [PubMed: 15081585]
56. He X, Li CM, Simonaro CM, et al. Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats. *Mol Genet Metab.* 1999; 67:106–112. [PubMed: 10356309]
57. Kanae Y, Endoh D, Yamato O, et al. Nonsense mutation of feline beta-hexosaminidase beta-subunit (*HEXB*) gene causing Sandhoff disease in a family of Japanese domestic cats. *Res Vet Sci.* 2007; 82:54–60. [PubMed: 16872651]
58. Crawley AC, Yogalingam G, Muller VJ, et al. Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes. *J Clin Invest.* 1998; 101:109–119. [PubMed: 9421472]
59. Goree M, Catalfamo JL, Aber S, et al. Characterization of the mutations causing hemophilia B in 2 domestic cats. *J Vet Intern Med.* 2005; 19:200–204. [PubMed: 15822564]
60. Fyfe JC, Kurzhals RL, Lassaline ME, et al. Molecular basis of feline beta-glucuronidase deficiency: an animal model of mucopolysaccharidosis VII. *Genomics.* 1999; 58:121–128. [PubMed: 10366443]
61. Somers K, Royals M, Carstea E, et al. Mutation analysis of feline Niemann-Pick C1 disease. *Mol Genet Metab.* 2003; 79:99–103. [PubMed: 12809639]
62. Goldstein R, Narala S, Sabet N, et al. Primary Hyperoxaluria in cats caused by a mutation in the feline *GRHPR* gene. *J Hered.* 2009; 100:S2–S7.
63. Lettice LA, Hill AE, Devenney PS, et al. Point mutations in a distant sonic hedgehog cis-regulator generate a variable regulatory output responsible for preaxial polydactyly. *Hum Mol Genet.* 2008; 17:978–985. [PubMed: 18156157]
64. Ginzinger DG, Lewis ME, Ma Y, et al. A mutation in the lipoprotein lipase gene is the molecular basis of chylomicronemia in a colony of domestic cats. *J Clin Invest.* 1996; 97:1257–1266. [PubMed: 8636438]

65. Berg T, Tollersrud OK, Walkley SU, et al. Purification of feline lysosomal alpha-mannosidase, determination of its cDNA sequence and identification of a mutation causing alpha-mannosidosis in Persian cats. *Biochem J.* 1997; 328 (Pt 3):863–870. [PubMed: 9396732]
66. Geisen V, Weber K, Hartmann K. Vitamin D-dependent hereditary rickets type I in a cat. *J Vet Intern Med.* 2009; 23:196–199. [PubMed: 19138382]
67. Mazrier H, Van Hoeven M, Wang P, et al. Inheritance, biochemical abnormalities, and clinical features of feline mucopolidosis II: the first animal model of human I-cell disease. *J Hered.* 2003; 94:363–373. [PubMed: 14557388]
68. Grahn R, Ellis M, Grahn J, et al. No bones about it! A novel CYP27B1 mutation results in feline vitamin D-dependent Rickets Type I (VDDR-1). 2011 in preparation.

The figure displays a protein sequence and a corresponding DNA sequence. The protein sequence is shown as a single line of single-letter codes: P...N...R...G... The DNA sequence is shown as a single line of single-letter codes: C...G...G...C... A mutation site is highlighted in the DNA sequence, showing a change from G to C. The mutation site is located between the second and third amino acids (N and R).

**Figure 1. Genetic sequence for the cat “points” mutation**

a) Protein sequence, b) DNA sequence. The letters on the top line are the single letter codes for amino acids, for example, a P is proline, an N is asparagine, an R is arginine, and a G is glycine. The top line is the sequence for a normal, non-pointed cat. The second line is the sequence in humans, the third is the Siamese-pointed cat, and the bottom line is the sequence for the domestic dog. c) A Dominant white Siberian cat with yellow eyes had one allele for points but the other allele had a normal DNA variant. This variant did not change the amino acid, this is silent. A genetic test that incorporates this sequence surrounding the mutation for points may fail in some cats, producing allelic drop-out. The cat would have a result of homozygous for points. All pointed cats must have blue eyes, thus, this variant was identified and the genetic assay changed to account for this possibility in the flanking genetic sequencing.

Table 1

Common commercialized DNA tests for domestic cats.

Disease/Trait	MOI <sup>‡</sup>	Phenotype	Breeds	Gene	Mutation
Agouti <sup>40</sup>	AR	Banded fur to solid	All breeds	<i>ASIP</i>	del122-123
Amber <sup>41</sup>	AR	Brown color variant	Norwegian Forest	<i>MC1R</i>	G250A
Brown <sup>42,43</sup>	AR	Brown, light brown color variants	All breeds	<i>TYRP1</i>	b = C8G, b <sup>1</sup> = C298T
Color <sup>37,43,44</sup>	AR	Burmese, Siamese color pattern, full albino	All breeds	<i>TYR</i>	c <sup>b</sup> = G715T, c <sup>a</sup> = G940A, c = C975del
Dilution <sup>45</sup>	AR	Black to grey/blue, Orange to cream	All breeds	<i>MLPH</i>	T83del
Gloves <sup>46</sup>	AR	White feet	Birman		
Hairless (Naked) <sup>47</sup>	AR	Atrichia	Sphynx	<i>KRT71</i>	
Long fur <sup>5,6</sup>	AR	long fur	All breeds <sup>§</sup>	<i>FGF5</i>	c.356insT, C406T, c.474delT, A475C
Rexing (curly fur) <sup>47</sup>	AR	Curly hair coat	Devon Rex	<i>KRT71</i>	
AB Blood Type <sup>39</sup>	AR	Determines Type B	All breeds	<i>CMAH</i>	18indel-53, G139A
Gangliosidosis 1 <sup>48</sup>	AR	Lipid storage disorder	Korat, Siamese	<i>GBLI</i>	G1457C
Gangliosidosis 2 <sup>49</sup>	AR	Lipid storage disorder	Burmese	<i>HEXB</i>	1.5bp del (intron)
Gangliosidosis 2 <sup>50</sup>	AR	Lipid storage disorder	Korat	<i>HEXB</i>	C39del
Glycogen Storage Dis. IV <sup>51</sup>	AR	Glycogen storage disorder	Norwegian Forest	<i>GBE1</i>	230bp ins 5' - 6kb del
Hypertrophic Cardiomyopathy <sup>26</sup>	AD	Cardiac disease	Maine Coon	<i>MYBPC</i>	G93C
Hypertrophic Cardiomyopathy <sup>31</sup>	AD	Cardiac Disease	Ragdoll	<i>MYBPC</i>	C2460T
Progressive Retinal Atrophy <sup>52</sup>	AR	Late onset blindness	Abyssinian	<i>CEP290</i>	IVS50 + 9T>G
Progressive Retinal Atrophy <sup>53</sup>	AD	Early onset blindness	Abyssinian	<i>CRX</i>	n.546delC
Polycystic Kidney Disease <sup>15</sup>	AD	Kidney cysts	Persian	<i>PKDI</i>	C10063A
Pyruvate Kinase Def. <sup>7</sup>	AR	Hemopathy	Abyssinian	<i>PKLR</i>	13bp del in exon 6
Spinal Muscular Atrophy <sup>54</sup>	AR	Muscular atrophy	Maine Coon	<i>LIX1-LNPEP</i>	140kb del, exons 4-6

<sup>‡</sup> Unpublished test, presented only as abstract.

<sup>‡</sup> Mode of inheritance of the non-wildtype variant,

<sup>§</sup> Long fur variants are more or less common depending on the breed.



Table 2

Other Mutations for Inherited Domestic Cat Diseases<sup>†</sup>.

Disease	Gene	Mutation	Disease	Gene	Mutation
Gangliosidosis 2 <sup>55</sup>	HEXB	inv1467-1491	Mucopolysaccharidosis I <sup>56</sup>	IDUA	del1047-1049
Gangliosidosis 2 <sup>57</sup>	HEXB	C667T	Mucopolysaccharidosis VI <sup>2</sup>	ARSB	T1427C
Gangliosidosis 2 <sup>51</sup>	GM2A	del390-393	Mucopolysaccharidosis VI <sup>9,58</sup>	ARSB	G1558A
Hemophilia B <sup>59</sup>	F9	G247A	Mucopolysaccharidosis VII <sup>60</sup>	GUSB	A1052G
Hemophilia B <sup>59</sup>	F9	C1014T	Niemann-Pick C <sup>61</sup>	NPC	G2864C
Hyperoxaluria <sup>62</sup>	GRHPR	G>A I4 acceptor site	Polydactyla <sup>63</sup>	SHH	A479G
Lipoprotein Lipase Def. <sup>64</sup>	LPL	G1234A	Polydactyla <sup>63</sup>	SHH	G257C, A481T
Mannosidosis, alpha <sup>65</sup>	LAMAN	del1748-1751	Vitamin D Resistant Rickets <sup>66</sup>	CYP27B1	G223A, G731del
Mucopolipidosis II <sup>67</sup>	GNPTA	C2655T	Vitamin D Resistant Rickets <sup>68</sup>	CYP27B1	G637T

<sup>†</sup>The presented conditions are not prevalent in breeds or populations but may have been established into research colonies.

Table 3

Domestic Cat DNA testing laboratories.

Lab/Webpage	Region	Univ. Research Affiliate	ID	Cat Test <sup>†</sup> / Disease	Color	Blood	Coat
Animal DNA Testing www.animalsdna.com	Australia		Yes	4	Some	Yes	No
Animal Health Trust www.aht.org.uk	UK	Animal Health Trust	Yes	PKD	No	No	No
Antagene Immeuble Le Meltem www.antagene.com	France		Yes	4	Color	Yes	No
BioAxis DNA Research Centre Ltd. www.dnares.in	India		Yes	PKD	No	No	No
DNA Diagnostics Center www.dnacenter.com	USA		No	PKD	No	No	No
GENINDEXE www.genindexe.com	France		Yes	7	5	Yes	No
Genosoper www.genosoper.com	Finland		Yes	No	No	Yes	No
Gribbles www.gribblesvets.com	Australia		No	PKD	No	No	No
IDEXX www.idexx.ca	Canada		No	PK def.	No	No	No
Laboklin www.laboklin.de/	Germany		Yes	9	5	Yes	Long
Langford Veterinary Services, Molecular Diagnostics Unit, Langfordvets.co.uk	UK	Bristol	No	3	No	No	No
PennGen research.vet.upenn.edu/penngen <sup>†</sup>	USA	Pennsylvania	No	PK GSD	No	No	No
PROGENUS S.A. www.progenus.be	Belgium		Yes	HCM PKD	No	No	No
Van Haeringen Laboratory www.vhlgenetics.com	Netherlands		Yes	9	5	Yes	Long
Veterinary Cardiac Genetics Lab VCGL@vetmed.wsu.edu	USA	Washington St.	No	HCM	No	No	No
Veterinary Genetics Lab www.vgl.lucdavis.edu	USA	California, Davis	Yes	7	All	Yes	All
VetGen www.vetgen.com	USA	Michigan	Yes	No	Brown Dilute	No	Long
Vetogene www.vetogene.com	Italy	Milan	Yes	HCM PKD	No	No	No

<sup>†</sup> Tests reference to those listed in Table 1. If a laboratory offers only one or two test, those tests are listed. PKD and the HCMs are the most popular tests to offer.

<sup>‡</sup> PennGen also offers tests for diseases in Table 2 that are not of concern to the cat breeds or population in general.